Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GHSI Guardion Health Sciences	$3.22 -2.1%	$3.24	$3.04 ▼ $18.00	$4.35M	0.73	105,261 shs	4,700 shs
JAGX Jaguar Animal Health	$3.05 +13.0%	$6.07	$2.61 ▼ $110.75	$2.75M	0.68	52,263 shs	107,514 shs
SXTP 60 Degrees Pharmaceuticals	$2.35 +9.3%	$2.51	$1.41 ▼ $35.99	$3.17M	2.88	574,340 shs	71,630 shs
TRVN Trevena	$1.13 +2.5%	$1.15	$0.95 ▼ $7.85	$1.08M	0.63	2,056 shs	863 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GHSI Guardion Health Sciences	0.00%	0.00%	0.00%	0.00%	-67.47%
JAGX Jaguar Animal Health	+12.96%	-5.57%	-32.07%	-40.55%	-96.78%
SXTP 60 Degrees Pharmaceuticals	+9.30%	+13.53%	+16.92%	+25.00%	+67.68%
TRVN Trevena	+2.45%	-1.14%	+6.42%	-11.95%	-79.91%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GHSI Guardion Health Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
JAGX Jaguar Animal Health	2.1134 of 5 stars	3.5	5.0	0.0	0.0	0.0	0.0	0.6
SXTP 60 Degrees Pharmaceuticals	3.1766 of 5 stars	3.3	5.0	0.0	0.0	0.0	2.5	0.6
TRVN Trevena	1.8056 of 5 stars	3.0	5.0	0.0	0.0	0.6	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GHSI Guardion Health Sciences	0.00	N/A	N/A	N/A
JAGX Jaguar Animal Health	3.00	Buy	$60.00	1,867.21% Upside
SXTP 60 Degrees Pharmaceuticals	2.50	Moderate Buy	$7.00	197.87% Upside
TRVN Trevena	2.00	Hold	$5.00	343.66% Upside

Current Analyst Ratings Breakdown

Latest JAGX, TRVN, SXTP, and GHSI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	SXTP 60 Degrees Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
6/2/2025	SXTP 60 Degrees Pharmaceuticals	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$5.80 ➝ $7.00
5/24/2025	SXTP 60 Degrees Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
5/19/2025	JAGX Jaguar Animal Health	First Berlin Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00
5/10/2025	SXTP 60 Degrees Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
4/24/2025	SXTP 60 Degrees Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
4/8/2025	SXTP 60 Degrees Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
3/28/2025	SXTP 60 Degrees Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral

(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GHSI Guardion Health Sciences	$12.25M	0.35	$0.14 per share	23.15	$6.39 per share	0.50
JAGX Jaguar Animal Health	$11.69M	0.27	N/A	N/A	$12.29 per share	0.25
SXTP 60 Degrees Pharmaceuticals	$300K	11.52	N/A	N/A	($6.38) per share	-0.37
TRVN Trevena	$443K	2.44	N/A	N/A	($11.07) per share	-0.10

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GHSI Guardion Health Sciences	$160K	$4.87	0.66	∞	N/A	22.79%	-73.69%	-48.17%	N/A
JAGX Jaguar Animal Health	-$38.49M	N/A	0.00	N/A	N/A	-343.92%	-432.91%	-71.25%	8/12/2025 (Estimated)
SXTP 60 Degrees Pharmaceuticals	-$7.95M	-$50.41	N/A	N/A	N/A	-1,947.30%	N/A	-174.90%	8/13/2025 (Estimated)
TRVN Trevena	-$40.29M	-$47.04	N/A	N/A	N/A	N/A	N/A	-119.55%	8/6/2025 (Estimated)

Latest JAGX, TRVN, SXTP, and GHSI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/15/2025	Q1 2025	JAGX Jaguar Animal Health	-$18.50	-$16.70	+$1.80	-$16.70	$3.29 million	$3.50 million
5/15/2025	Q1 2025	SXTP 60 Degrees Pharmaceuticals	-$1.31	-$1.56	-$0.25	-$1.56	$0.15 million	$0.18 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GHSI Guardion Health Sciences	$5.00	155.28%	N/A	102.67%	N/A
JAGX Jaguar Animal Health	N/A	N/A	N/A	N/A	N/A
SXTP 60 Degrees Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TRVN Trevena	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GHSI Guardion Health Sciences	N/A	16.68	16.59
JAGX Jaguar Animal Health	22.20	1.08	0.70
SXTP 60 Degrees Pharmaceuticals	N/A	3.14	2.71
TRVN Trevena	N/A	2.42	2.42

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GHSI Guardion Health Sciences	20.21%
JAGX Jaguar Animal Health	12.04%
SXTP 60 Degrees Pharmaceuticals	7.96%
TRVN Trevena	13.56%

Insider Ownership

Company	Insider Ownership
GHSI Guardion Health Sciences	1.32%
JAGX Jaguar Animal Health	0.38%
SXTP 60 Degrees Pharmaceuticals	10.27%
TRVN Trevena	2.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GHSI Guardion Health Sciences	10	1.35 million	1.33 million	Not Optionable
JAGX Jaguar Animal Health	50	1.02 million	1.01 million	No Data
SXTP 60 Degrees Pharmaceuticals	3	1.47 million	1.32 million	Not Optionable
TRVN Trevena	40	959,000	841,000	Optionable

JAGX, TRVN, SXTP, and GHSI Headlines

Recent News About These Companies

Trevena Enters Securities Exchange Agreement with Investor

May 15, 2025 | tipranks.com

Berks sports roundup: Alex Trevena helps Conrad Weiser to 8-5 softball win

April 11, 2025 | readingeagle.com

Vanessa Hudgens and Oliver Trevena Appear at Expo West for Caliwater

March 9, 2025 | msn.com

JMP Securities downgrades Trevena (TRVN) to a Hold

December 28, 2024 | markets.businessinsider.com

‘Plane’ Actor Oliver Trevena Signs With Untitled Entertainment

December 16, 2024 | yahoo.com

Lyme Regis town councillor John Trevena stand down

December 11, 2024 | bridportnews.co.uk

Trevena (TRVN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

December 10, 2024 | zacks.com

Trevena appoints new financial chief

November 29, 2024 | investing.com

Trevena Appoints Katrine Sutton as New CFO

November 27, 2024 | tipranks.com

HC Wainwright & Co. Downgrades Trevena (TRVN)

November 16, 2024 | msn.com

Trevena, Inc. Navigates Financial Challenges and Strategic Changes

November 9, 2024 | msn.com

Chester County biopharm firm's latest layoffs impact its C-suite

November 7, 2024 | bizjournals.com

Trevena teeters in dangerous territory, terminating CEO and other execs amid strategic review

November 7, 2024 | fiercebiotech.com

Trevena Reports Third Quarter 2024 Results and Provides Business Update

November 7, 2024 | globenewswire.com

Why Trevena (TRVN) Stock Is Down 43% Today

October 8, 2024 | msn.com

Trevena, Inc. Faces Delisting from Nasdaq

October 6, 2024 | msn.com

Trevena Announces Receipt of Nasdaq Delisting Notification

October 4, 2024 | globenewswire.com

Learn to Evaluate (TRVN) using the Charts

September 16, 2024 | news.stocktradersdaily.com

Trevena (NASDAQ:TRVN) Stock Quotes, Forecast and News Summary

September 12, 2024 | benzinga.com

Trevena Inc (TRVN) Stock: Surpassing Expectations in the Market?

September 11, 2024 | bovnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

JAGX, TRVN, SXTP, and GHSI Company Descriptions

Guardion Health Sciences NASDAQ:GHSI

Guardion Health Sciences, Inc., a clinical nutrition company, develops and distributes clinically supported dietary supplements and medical foods in North America, Europe, and internationally. The company offers GlaucoCetin, a dietary supplement to support mitochondrial function with additional antioxidants to help reduce oxidative stress and increase blood flow throughout the body for enhanced eye support and ocular health; and Lumega-Z, a medical food that replenishes and restores the macular protective pigment. It also provides Viactiv Omega Boost Gel Bites, an omega-3 fish oil dietary supplement. The company distributes medical foods products through e-commerce website, guardionhealth.com. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in Houston, California.

Jaguar Animal Health NASDAQ:JAGX

$3.05 +0.35 (+12.96%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$2.99 -0.06 (-1.97%)

As of 04:03 AM Eastern

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.

60 Degrees Pharmaceuticals NASDAQ:SXTP

$2.35 +0.20 (+9.30%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$2.29 -0.06 (-2.72%)

As of 04:00 AM Eastern

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.

Trevena NASDAQ:TRVN

$1.13 +0.03 (+2.45%)

As of 06/24/2025 01:38 PM Eastern

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time